» Articles » PMID: 23508695

Evoked Potentials and Neurocognitive Functions in Pediatric Egyptian Gaucher Patients on Enzyme Replacement Therapy: a Single Center Experience

Overview
Publisher Wiley
Date 2013 Mar 20
PMID 23508695
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Effectiveness of enzyme replacement therapy (ERT) in reverting hematologic, skeletal, and visceral symptoms in Gaucher disease (GD) has been demonstrated, although, its efficacy in neurologic involvement is still debated.

Aim: We evaluated the extent of neuro-cognitive dysfunction using brain stem evoked potential in GD3 patients, age-matched controls, and GD1 patients without neurological manifestations served as disease control group.

Methods: Study included 56 GD (36 had type 1, 20 had type 3) under ERT. Investigations included complete blood count, beta glucosidase assay in peripheral leucocytes, plasma chitotriosidase and bone marrow examination, electroencephalography, brain stem auditory (AEP), somatosensory (SSEP) and visual evoked potentials (VEP) as well as IQ testing.

Results: Both types of GD showed significantly higher mean latency at 75 on left eye, lower PP amplitude ratio, higher latency at 75, 100, 145, lower amplitude, and higher Lat Diff LT-RT ms and Lt-Rt % compared to controls (p < 0.05) with no difference between both groups in other values of VEP. Both groups showed significantly prolonged latency of N 13-19 compared to controls (p < 0.05) with positive correlation between age and duration of therapy with parameters of SSEP (p < 0.01). Both groups of GD had significantly prolonged latency of the mean waves of AEP compared to controls (p < 0.05) with no significant difference between both groups. There was a negative correlation between age and waves II, III, I-III, I-V and threshold values of AEP. IQ level was positively correlated with AEP values. Severity scoring tool was positively correlated with AEP and SSEP values.

Conclusions: Electrophysiological abnormalities were present in both types of GD and have been correlated to cognitive function and disease characteristics.

Citing Articles

The Spectrum of Neurological and Sensory Abnormalities in Gaucher Disease Patients: A Multidisciplinary Study (SENOPRO).

Tullo M, Cerulli Irelli E, Caramia F, Tessari G, Di Bonaventura C, Turchetta R Int J Mol Sci. 2023; 24(10).

PMID: 37240189 PMC: 10218502. DOI: 10.3390/ijms24108844.


Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease.

Tsitsi P, Markaki I, Waldthaler J, Machaczka M, Svenningsson P JIMD Rep. 2022; 63(1):93-100.

PMID: 35028274 PMC: 8743341. DOI: 10.1002/jmd2.12262.


Decreased Wave V Amplitude in Auditory Brainstem Responses of Children with Cerebellar Lesions.

Matsuura Y, Oguri M, Saito Y, Aoe Y, Ogawa A, Akiyama S Yonago Acta Med. 2019; 61(4):220-227.

PMID: 30636918 PMC: 6308102.


Recent advances in the diagnosis and management of Gaucher disease.

Gary S, Ryan E, Steward A, Sidransky E Expert Rev Endocrinol Metab. 2018; 13(2):107-118.

PMID: 30058864 PMC: 6129380. DOI: 10.1080/17446651.2018.1445524.


Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey.

Schwartz I, Goker-Alpan O, Kishnani P, Zimran A, Renault L, Panahloo Z Mol Genet Metab Rep. 2018; 14:73-79.

PMID: 29326879 PMC: 5758841. DOI: 10.1016/j.ymgmr.2017.10.011.


References
1.
Bamiou D, Campbell P, Liasis A, Page J, Sirimanna T, Boyd S . Audiometric abnormalities in children with Gaucher disease type 3. Neuropediatrics. 2001; 32(3):136-41. DOI: 10.1055/s-2001-16611. View

2.
Beutler E . Gaucher disease: new molecular approaches to diagnosis and treatment. Science. 1992; 256(5058):794-9. DOI: 10.1126/science.1589760. View

3.
Ashkenazi A, Zaizov R, MATOTH Y . Effect of splenectomy on destructive bone changes in children with chronic (Type I) Gaucher disease. Eur J Pediatr. 1986; 145(1-2):138-41. DOI: 10.1007/BF00441877. View

4.
Vellodi A, Tylki-Szymanska A, Davies E, Kolodny E, Bembi B, Collin-Histed T . Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis. 2009; 32(5):660-664. DOI: 10.1007/s10545-009-1164-2. View

5.
Martins A, Valadares E, Porta G, Coelho J, Semionato Filho J, Pianovski M . Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr. 2009; 155(4 Suppl):S10-8. DOI: 10.1016/j.jpeds.2009.07.004. View